AR125144A1 - Nuevo proceso - Google Patents

Nuevo proceso

Info

Publication number
AR125144A1
AR125144A1 ARP220100637A ARP220100637A AR125144A1 AR 125144 A1 AR125144 A1 AR 125144A1 AR P220100637 A ARP220100637 A AR P220100637A AR P220100637 A ARP220100637 A AR P220100637A AR 125144 A1 AR125144 A1 AR 125144A1
Authority
AR
Argentina
Prior art keywords
compound
formula
preparation
new process
hcl
Prior art date
Application number
ARP220100637A
Other languages
English (en)
Inventor
Jean Adam
- Pfleger Christophe Michel
Georg Wuitschik
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR125144A1 publication Critical patent/AR125144A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a un proceso para la preparación de derivados de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-(2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4-ona que son útiles como compuestos farmacéuticamente activos. Reivindicación 1: Un proceso para la preparación de un compuesto de fórmula (1) o la sal de HCl de este, que comprende hacer reaccionar un compuesto de fórmula (2); con un ácido fuerte, en particular, HCl. Reivindicación 18: Un compuesto de las fórmulas (2), (3), (4), (5), (5-tautómero) o (6).
ARP220100637A 2021-03-18 2022-03-18 Nuevo proceso AR125144A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21163301 2021-03-18

Publications (1)

Publication Number Publication Date
AR125144A1 true AR125144A1 (es) 2023-06-14

Family

ID=75108126

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220100637A AR125144A1 (es) 2021-03-18 2022-03-18 Nuevo proceso

Country Status (12)

Country Link
EP (1) EP4308578A2 (es)
JP (1) JP2024509995A (es)
KR (1) KR20230145461A (es)
CN (1) CN117015546A (es)
AR (1) AR125144A1 (es)
AU (1) AU2022237836A1 (es)
BR (1) BR112023018593A2 (es)
CA (1) CA3210678A1 (es)
IL (1) IL304848A (es)
MX (1) MX2023010761A (es)
TW (1) TW202302605A (es)
WO (1) WO2022194909A2 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015261046C1 (en) 2014-05-15 2019-07-25 F. Hoffmann-La Roche Ag Compounds for treating spinal muscular atrophy
SG11202002610TA (en) 2017-09-22 2020-04-29 Hoffmann La Roche Process for the prepration of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives

Also Published As

Publication number Publication date
IL304848A (en) 2023-09-01
EP4308578A2 (en) 2024-01-24
MX2023010761A (es) 2023-09-22
TW202302605A (zh) 2023-01-16
BR112023018593A2 (pt) 2023-10-24
KR20230145461A (ko) 2023-10-17
JP2024509995A (ja) 2024-03-05
WO2022194909A2 (en) 2022-09-22
WO2022194909A3 (en) 2023-04-06
CA3210678A1 (en) 2022-09-22
AU2022237836A1 (en) 2023-07-27
CN117015546A (zh) 2023-11-07

Similar Documents

Publication Publication Date Title
AR112828A1 (es) Proceso para la preparación de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-(2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4-ona
US11395822B2 (en) Methods for treating Huntington's disease
US11382918B2 (en) Methods for treating Huntington's Disease
CY1119813T1 (el) Αλατα 2-φθορο-ν-μεθυλ-4-[7-(κινολιν-6-υλ-μεθυλ)-ιμιδαζο[1,2-β][1,2,4]τριαζιν-2-υλ]βενζαμιδιου και διαδικασιες που σχετιζονται με την παρασκευη αυτων
MX2021004487A (es) Nuevas formas de derivados de pirido[1,2-a]pirimidin-4-ona, su formulacion y su proceso de elaboracion.
MX2010006212A (es) Compuestos organicos.
MX352831B (es) Cristales de sal.
EA201170771A1 (ru) Органические соединения
WO2010012781A3 (en) New crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4- triazolo[4,3-a]pyrazine derivative
AU2015244044A1 (en) Treatment of B-cell malignancies by a combination JAK and PI3K inhibitor
PE20171104A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
NZ601754A (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
EA201170770A1 (ru) Органические соединения
TW200738243A (en) Novel process and formulations
HK1154574A1 (en) Salts of tetrahydroimidazo [1,5-a] pyrazine derivatives, preparation methods and pharmaceutical use thereof
SA520412290B1 (ar) مركبات جديدة مثبطة للهدف الميكانيكي للراباميسين
EA200800920A1 (ru) Производные пиразоло[4,3-d]пиримидин-5-ила, применяемые в качестве ингибиторов фосфодиэстеразы 5 (pde5)
AR125144A1 (es) Nuevo proceso
HRP20231276T1 (hr) Inhibitor egfr-a za liječenje raka
MY165623A (en) 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
MY156428A (en) HYDRATE OF 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETHYL)-5,8-DIHYDROPYRIDO[3,4-d]PYRIMIDIN-7(6H)-YL]-4-OXOBUTYL} -5,5-DIFLUORO-PIPERIDIN-2-ONE TARTRATE
WO2023147603A3 (en) Salt crystals
AR128043A1 (es) Sales y formas sólidas de un inhibidor de fgfr y procesos para su preparación
WO2023034965A3 (en) Co-crystals
TN2010000530A1 (en) Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same